Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Aardvark Therapeutics, Inc.: Amended and restated bylaws effective immediately prior to IPO, establishing procedures for stockholder proposals and director nominations, modifying indemnification provisions, and conforming to amended certificate (effective 2025-02-14).
- Change
- bylaw amendment
- Effective
- 2025-02-14
Exact text from the filing
the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders, became effective as of immediately prior to the completion of the IPO on February 14, 2025
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Aardvark Therapeutics, Inc.: Amended and restated certificate of incorporation in connection with IPO, including increasing authorized common stock to 490M shares, eliminating preferred stock references, authorizing 10M undesignated preferred shares, requiring two-thirds vote for director removal, establishing classified board, (effective 2025-02-14).
- Change
- charter amendment
- Effective
- 2025-02-14
Exact text from the filing
on February 14, 2025, the Company filed its fourth amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware
View on SEC.gov